Immunogenicity and Safety Study of SK SARS-CoV-2 Recombinant Nanoparticle Vaccine (GBP510) Adjuvanted With AS03 (COVID-19)

NCT05007951 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

4036

Enrollment

INDUSTRY

Sponsor class

Conditions

Covid19

Interventions

BIOLOGICAL: GBP510 adjuvanted with AS03 (Receptor-Binding Domain(RBD) 25ug/dose)
BIOLOGICAL: ChAdOx1-S not less than 2.5 × 10^8 infectious units
BIOLOGICAL: GBP510 adjuvanted with AS03 (Receptor-Binding Domain(RBD) 25ug/dose)

Sponsor

SK Bioscience Co., Ltd.

Collaborators

[object Object]
[object Object]
[object Object]